PW Medtech Group (1358) H1 2025 earnings summary

Executive summary

• Revenue rose 22.4% year-over-year to RMB414.4 million, driven by strong Blood Purification Business growth and the debut of Regenerative Medical Biomaterials revenue.

• Gross profit increased 13.4% to RMB212.8 million, with gross margin at 51.3%, down from 55.4% due to pricing pressure and product mix.

• Profit attributable to owners declined 6.0% to RMB66.0 million, mainly due to higher expenses and lower finance income.

• Adjusted profit attributable to owners (non-HKFRS) rose 10.9% to RMB83.4 million, reflecting adjustments for share-based compensation, spin-off costs, and amortization.

• Interim dividend of HK4.4 cents per share declared.

Financial highlights

• Blood Purification Business revenue surged 44.5% year-over-year to RMB297.4 million, now 71.8% of total revenue.

• Infusion Set Business revenue fell 14.5% to RMB113.4 million, impacted by volume-based procurement and soft demand.

• Regenerative Medical Biomaterials Business recorded RMB3.5 million in its first revenue contribution.

• Operating profit dropped 5.1% to RMB80.2 million; net finance income fell 17.5% to RMB22.9 million.

• Cash and cash equivalents stood at RMB1,693.3 million as of June 30, 2025.

Outlook and guidance

• Focus remains on expanding production, product portfolio, and international markets, especially for blood purification products.

• Continued R&D investment and product registration efforts across all segments.

• Management expects Regenerative Medical Biomaterials to become a new growth engine.

• Ongoing response to centralized procurement and market reforms to maintain competitiveness.

• Management sees opportunities in domestic substitution and international expansion despite procurement challenges.